- Home
- ESPR vs AVK Comparison
ESPR vs AVK Comparison
Compare ESPR & AVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- AVK
- Stock Information
- Founded
- ESPR 2008
- AVK 2003
- Country
- ESPR United States
- AVK United States
- Employees
- ESPR N/A
- AVK N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- AVK Trusts Except Educational Religious and Charitable
- Sector
- ESPR Health Care
- AVK Finance
- Exchange
- ESPR Nasdaq
- AVK Nasdaq
- Market Cap
- ESPR 534.3M
- AVK 571.7M
- IPO Year
- ESPR 2013
- AVK N/A
- Fundamental
- Price
- ESPR $2.97
- AVK $12.99
- Analyst Decision
- ESPR Buy
- AVK
- Analyst Count
- ESPR 6
- AVK 0
- Target Price
- ESPR $6.50
- AVK N/A
- AVG Volume (30 Days)
- ESPR 7.1M
- AVK 112.9K
- Earning Date
- ESPR 11-06-2025
- AVK 01-01-0001
- Dividend Yield
- ESPR N/A
- AVK 11.85%
- EPS Growth
- ESPR N/A
- AVK N/A
- EPS
- ESPR N/A
- AVK N/A
- Revenue
- ESPR $268,125,000.00
- AVK N/A
- Revenue This Year
- ESPR $18.83
- AVK N/A
- Revenue Next Year
- ESPR N/A
- AVK N/A
- P/E Ratio
- ESPR N/A
- AVK N/A
- Revenue Growth
- ESPR N/A
- AVK N/A
- 52 Week Low
- ESPR $0.69
- AVK $9.24
- 52 Week High
- ESPR $3.94
- AVK $12.16
- Technical
- Relative Strength Index (RSI)
- ESPR 59.21
- AVK 59.38
- Support Level
- ESPR $2.80
- AVK $12.83
- Resistance Level
- ESPR $3.11
- AVK $13.06
- Average True Range (ATR)
- ESPR 0.17
- AVK 0.16
- MACD
- ESPR 0.01
- AVK 0.01
- Stochastic Oscillator
- ESPR 76.47
- AVK 88.14
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.